Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer.
10.3760/cma.j.cn.441530-20210209-00060
- Collective Name:Committee of Colorectal Cancer, Chinese Southern Oncology Group
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Colorectal neoplasms;
Expert consensus;
FOLFOXIRI
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Camptothecin/therapeutic use*;
China;
Colorectal Neoplasms/drug therapy*;
Consensus;
Fluorouracil/therapeutic use*;
Humans;
Irinotecan/therapeutic use*;
Leucovorin/therapeutic use*;
Organoplatinum Compounds/therapeutic use*;
Oxaliplatin;
Treatment Outcome
- From:
Chinese Journal of Gastrointestinal Surgery
2021;24(6):473-479
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal cancer is the second most common malignant tumor in China. The FOLFOXIRI regimen, which combines 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan, is a high-intensity and highly effective chemotherapy regimen. However, the original regimen is poorly tolerated in Chinese patients. In order to promote the standardized and rational application of FOLFOXIRI regimen by clinicians in China, "
